You cant easily patent a naturally occurring amino acid sequence, which means theres been limited commercial incentive to fund large human trials for many of these compounds
FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding On September 29, 2023, updates were made to the list of bulk drug substances nominated for use under Section 503A
Simple timing framework Baseline Discuss baseline labs before starting, especially with active injury, infection concern, liver disease, kidney disease, anemia, or copper metabolism concerns
RotroffDCorumDMotsinger-ReifAFiehnOBottrelNDrevetsWet alMetabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: New mechanistic insights for rapid acting antidepressants
NMR Structural Resolution of FOXO4-DRI/p53TAD2 Complex (Nature Communications, 2025) Disordered-to-Ordered Complex Formation: Structural Basis of FOXO4-DRIs Senolytic Mechanism A landmark structural study published in Nature Communications (2025) resolved the solution NMR structural models of the p53 transactivation domain (TAD2) in complex with the FOXO4 forkhead domain and with FOXO4-DRI